Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

EZH2 inhibition synergizes with aiolos/ikaros degradation via coordinated chromatin remodeling and FoxO activation in multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

AGAnita K. Gandhi

Discussion

Loading...

Member takes

Overview

Observational analysis shows enhanced pharmacological effects with ezh2 inhibition in multiple myeloma, suggesting a novel therapeutic strategy.

Key Points

  • Ezh2 inhibition revealed chromatin remodeling enhancing celmod efficacy in multiple myeloma cells, promoting apoptosis.
  • Pharmacological effects were evaluated via rna-sequencing and chip-seq, showing upregulation of apoptotic genes.
  • Chromatin immunoprecipitation sequencing analysis indicated reduction of h3k27me3 marks at pro-apoptotic gene loci.
  • Findings highlight potential dual-targeted approaches to overcome therapeutic resistance in multiple myeloma.

Cite This Study

Anita K. Gandhi (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d3eahttps://doi.org/10.1182/blood-2025-5699
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Pharmacodynamic activity and clinical benefits of mezigdomide in high-risk biomarker subgroups from the CC-92480-MM-001 study2025 · 1 citations
  2. 2Epigenetic reprogramming via EZH1/2 inhibition enhances T cell-mediated immunotherapies against multiple myeloma2025
  3. 3Ikaros degradation by mezigdomide reduces T-cell dysfunction and improves the efficacy of antimyeloma T-cell therapies2026 · 4 citations
  4. 4Targeting degradation of IKZF1 and IKZF3 through modulation of the E3 ligase substrates in the context of cellular therapies for multiple myeloma2025 · 7 citations
  5. 5Mezigdomide overcomes CRBN mutations emerging post IMiD therapy2025 · 1 citations